Found: 40
Select item for more details and to access through your institution.
An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects.
- Published in:
- Journal of Gene Medicine, 2004, v. 6, n. 8, p. 937, doi. 10.1002/jgm.578
- By:
- Publication type:
- Article
Observations on the Effects of Residualization and Dehalogenation on the Utility of N-Succinimidyl Ester Acylation Agents for Radioiodination of the Internalizing Antibody Trastuzumab.
- Published in:
- Molecules, 2019, v. 24, n. 21, p. 3907, doi. 10.3390/molecules24213907
- By:
- Publication type:
- Article
d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate Substitution.
- Published in:
- Molecules, 2018, v. 23, n. 5, p. 1223, doi. 10.3390/molecules23051223
- By:
- Publication type:
- Article
No-Carrier-Added Iodine-131-FIBG: Evaluation of an MIBG Analog.
- Published in:
- Journal of Nuclear Medicine, 1997, v. 38, n. 2, p. 330
- By:
- Publication type:
- Article
Validation of 4-[Fluorine- 18]Fluoro-3-Iodobenzylguanidine as a Positron-Emitting Analog of MIBG.
- Published in:
- Journal of Nuclear Medicine, 1995, v. 36, n. 4, p. 644
- By:
- Publication type:
- Article
Fluorine-18-Labeled Monoclonal Antibody Fragments: A Potential Approach for Combining Radioman and Positron Emission Topography.
- Published in:
- Journal of Nuclear Medicine, 1992, v. 33, n. 8, p. 1535
- By:
- Publication type:
- Article
Correction to: Switch-on effect on conformation-specific arylamine–DNA adduct by cyclometalated Ir(III) complexes.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Switch-on effect on conformation-specific arylamine–DNA adduct by cyclometalated Ir(III) complexes.
- Published in:
- Journal of Biological Inorganic Chemistry (JBIC), 2020, v. 25, n. 2, p. 305, doi. 10.1007/s00775-020-01762-7
- By:
- Publication type:
- Article
Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose <sup>211</sup>At-Labeled Anti-HER2 Single-Domain Antibody Fragment.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 1, p. 124, doi. 10.2967/jnumed.122.264071
- By:
- Publication type:
- Article
Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose <sup>211</sup>At-Labeled Anti-HER2 Single Domain Antibody Fragment.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.122.264071
- By:
- Publication type:
- Article
Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose <sup>211</sup>At-Labeled Anti-HER2 Single Domain Antibody Fragment.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.122.264071
- By:
- Publication type:
- Article
Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose <sup>211</sup>At-Labeled Anti-HER2 Single Domain Antibody Fragment.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.122.264071
- By:
- Publication type:
- Article
Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose <sup>211</sup>At-Labeled Anti-HER2 Single Domain Antibody Fragment.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.122.264071
- By:
- Publication type:
- Article
An improved 211At-labeled agent for PSMA-targeted alpha therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262098
- By:
- Publication type:
- Article
Site-Specific and Residualizing Linker for 18F-Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single Domain Antibody Fragment.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.261446
- By:
- Publication type:
- Article
An improved <sup>211</sup>At-labeled agent for PSMA-targeted alpha therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262098
- By:
- Publication type:
- Article
Site-Specific and Residualizing Linker for 18F-Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single Domain Antibody Fragment.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.261446
- By:
- Publication type:
- Article
An improved <sup>211</sup>At-labeled agent for PSMA-targeted alpha therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262098
- By:
- Publication type:
- Article
Site-Specific and Residualizing Linker for <sup>18</sup>F-Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single Domain Antibody Fragment.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.261446
- By:
- Publication type:
- Article
An improved <sup>211</sup>At-labeled agent for PSMA-targeted alpha therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.262098
- By:
- Publication type:
- Article
Site-Specific and Residualizing Linker for <sup>18</sup>F-Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single Domain Antibody Fragment.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.261446
- By:
- Publication type:
- Article
An improved <sup>211</sup>At-labeled agent for PSMA-targeted alpha therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.121.262098
- By:
- Publication type:
- Article
Site-Specific and Residualizing Linker for <sup>18</sup>F-Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single Domain Antibody Fragment.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.261446
- By:
- Publication type:
- Article
An improved <sup>211</sup>At-labeled agent for PSMA-targeted alpha therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.121.262098
- By:
- Publication type:
- Article
Site-Specific and Residualizing Linker for <sup>18</sup>F-Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single Domain Antibody Fragment.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.120.261446
- By:
- Publication type:
- Article
Site-Specific and Residualizing Linker for <sup>18</sup>F-Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single Domain Antibody Fragment.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.261446
- By:
- Publication type:
- Article
Site-Specific and Residualizing Linker for <sup>18</sup>F-Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single Domain Antibody Fragment.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 3, p. 1, doi. 10.2967/jnumed.120.261446
- By:
- Publication type:
- Article
(2S)-2-(3-(1-Carboxy-5-(4-<sup>211</sup>At-Astatobenzamido)Pentyl) Ureido)-Pentanedioic Acid for PSMA-Targeted a-Particle Radiopharmaceutical Therapy.
- Published in:
- Journal of Nuclear Medicine, 2016, v. 57, n. 10, p. 1569, doi. 10.2967/jnumed.116.174300
- By:
- Publication type:
- Article
Preclinical Evaluation of <sup>18</sup>F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.
- Published in:
- Journal of Nuclear Medicine, 2016, v. 57, n. 6, p. 967, doi. 10.2967/jnumed.115.171306
- By:
- Publication type:
- Article
Improved Tumor Targeting of Anti-HER2 Nanobody Through N-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling.
- Published in:
- Journal of Nuclear Medicine, 2014, v. 55, n. 4, p. 650, doi. 10.2967/jnumed.113.127100
- By:
- Publication type:
- Article
A tin precursor for the synthesis of no-carrier-added [*I]MIBG and [<sup>211</sup>At]MABG.
- Published in:
- Journal of Labelled Compounds & Radiopharmaceuticals, 2007, v. 50, n. 3, p. 177, doi. 10.1002/jlcr.1243
- By:
- Publication type:
- Article
Gold Nanostars: A Novel Platform for Developing <sup>211</sup>At-Labeled Agents for Targeted Alpha-Particle Therapy.
- Published in:
- International Journal of Nanomedicine, 2021, v. 16, p. 7297, doi. 10.2147/IJN.S327577
- By:
- Publication type:
- Article
Nucleobase Oxidation of DNA by (Terpyridyl)chromium(III) Derivatives.
- Published in:
- European Journal of Inorganic Chemistry, 2004, v. 2004, n. 9, p. 1840
- By:
- Publication type:
- Article
Synthesis, Characterization, and DNA Binding Studies of a Chromium(III) Complex Containing a Tridentate Ligand.
- Published in:
- European Journal of Inorganic Chemistry, 2003, v. 2003, n. 19, p. 3633
- By:
- Publication type:
- Article
Low-level whole-brain radiation enhances theranostic potential of single-domain antibody fragments for human epidermal growth factor receptor type 2 (HER2)-positive brain metastases.
- Published in:
- Neuro-Oncology Advances, 2022, v. 4, n. 1, p. 1, doi. 10.1093/noajnl/vdac135
- By:
- Publication type:
- Article
Synthesis and evaluation of F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2014, v. 41, n. 2, p. 322, doi. 10.1007/s00259-013-2558-9
- By:
- Publication type:
- Article
A 4-methyl-substitutedmeta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2004, v. 31, n. 10, p. 1362, doi. 10.1007/s00259-004-1596-8
- By:
- Publication type:
- Article
Conformation Specific Binding of [Ru(phen)<sub>2</sub>(dppz)]<sup>2+</sup> with Mono‐ and Cluster Arylamine‐DNA Adducts.
- Published in:
- ChemistrySelect, 2018, v. 3, n. 40, p. 11152, doi. 10.1002/slct.201802172
- By:
- Publication type:
- Article
Evaluation of an <sup>131</sup>I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-07006-9
- By:
- Publication type:
- Article
Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.
- Published in:
- 2017
- By:
- Publication type:
- journal article